OncoTargets and Therapy (Dec 2020)
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
Abstract
Yi Chen,1 Hao Zhang,2 Junfeng Shi,3,* Tongshan Wang2,* 1Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing 210000, People’s Republic of China; 2Department of Oncology, Jiangsu Provincial People’s Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, People’s Republic of China; 3Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tongshan WangDepartment of Oncology, Jiangsu Provincial People’s Hospital, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210000, People’s Republic of ChinaTel/Fax +86-25-68307102Email [email protected] ShiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, People’s Republic of ChinaTel/Fax +86-25-87726234Email [email protected]: We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In conclusion, camrelizumab may be a good treatment option, especially in tumors that express PD-L1.Keywords: camrelizumab, pulmonary pleomorphic carcinoma, immune checkpoint inhibitor, PD-1, reactive skin capillary endothelial cell proliferation, RCCEP
